SygRNA™ Cas9 Synthetic Modified tracrRNA

Description

• General description: The SygRNA modified synthetic RNA system recruits WT SpCas9, eSpCas9, dCas9, or Cas9D10A to specific genomic targets. 2′ O-methyl and phosphothioate modifications have been incorporated to enhance the stability and performance of the synthetic RNA. The modified tracrRNA (trans-activating crRNA) binds to a crRNA (CRISPR RNA) and the resulting crRNA-tracrRNA complex guides SpCas9 and SpCas9 variant proteins to crRNA-specified sites in the genome. SygRNA modified synthetic tracrRNA and crRNAs are optimized for use with a variety of Cas9 expressing cell lines, Cas9 proteins, or Cas9 mRNAs and are compatible with a delivery methods such as microinjection, lipofection, and electroporation.
• Application: Functional Genomics/Target Validation/TransgenicsCreation of gene knockouts in multiple cell linesComplete knockout of genes not amenable to RNAiCreation of knock-in cell lines with promoters, fusion tags, or reporters integrated into endogenous genesGeneration of transgenic animals via embryo microinjection or electroporation
• Features and Benefits: HPLC-purified SygRNA modified tracrRNA oligo is optimized for use with a target-specific crRNA or modified crRNA and a source of SpCas9 protein for genome editing applications.
• Linkage: The SygRNA Cas9 tracrRNA oligo is used in conjunction with a target-specific crRNA and a source of Cas9 protein to form active RNP complexes. Visit SigmaAldrich.com/CRISPRessentials to to review available Cas9 sources. Order crRNAs at SigmaAldrich.com/CRISPR
• Preparation Note: Resuspend SygRNA modified tracrRNA oligo in a RNAase-free Tris-containing buffer with a pH 8.0 or less.
• Legal Information: CRISPR Use License Agreement